Codexis to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 11
Rhea-AI Summary
Codexis (NASDAQ: CDXS) will report fourth quarter and fiscal year 2025 results on Wednesday, March 11, 2026 after market close. Management will host a conference call and webcast at 4:30 PM ET to discuss results and provide a business update.
The live webcast will be available on the Codexis Investor Relations website and archived for 90 days; a telephone replay will be available for 48 hours.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
CDXS is up 3.27% while momentum peers are mixed: PBYI up 4.14% and OABI down 4.05%, indicating a stock-specific move rather than a broad sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Conference participation | Positive | +0.8% | Announcement of TD Cowen healthcare conference fireside chat and webcast access. |
| Feb 10 | Quality certification | Positive | -3.1% | ISO 9001:2015 certification for core facilities and quality management systems. |
| Jan 07 | Platform evaluation deal | Positive | -1.2% | Axolabs evaluation agreement for ECO Synthesis oligonucleotide manufacturing platform. |
| Nov 10 | GMP facility lease | Positive | +3.5% | Signing of lease for 34,000 sq ft GMP facility to expand production capacity. |
| Nov 06 | Q3 2025 earnings | Negative | -5.3% | Q3 2025 results with revenue decline, restructuring, and extended cash runway through 2027. |
Recent news often shows mixed reactions, with some positive operational updates selling off while facility and earnings restructuring news aligned with price moves.
Over the past few months, Codexis has announced several operational milestones. In November 2025, it reported Q3 2025 results with a $37.8M Merck Supply Assurance Agreement, workforce reductions and an extended cash runway through 2027, and also signed a lease for a 34,000 sq ft GMP facility. In early 2026, the company signed an ECO Synthesis® evaluation agreement with Axolabs, obtained ISO 9001:2015 certification, and scheduled conference participation. Today’s earnings-date announcement fits into this pattern of ongoing strategic and operational updates.
Market Pulse Summary
This announcement schedules Codexis’s Q4 and FY 2025 results for March 11, 2026, with a conference call at 4:30 pm ET and a webcast archived for 90 days. Ahead of this, the stock traded at 1.105, near its 1.05 52-week low and below the 2.22 200-day MA. Recent updates included a new GMP facility, a Merck supply agreement, and ISO certification. Investors may focus on revenue trends, cash levels, and progress on the ECO Synthesis® platform when results are released.
AI-generated analysis. Not financial advice.
REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the fourth quarter and fiscal year 2025 on Wednesday, March 11, 2026, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.
Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis® manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Georgia Erbez
(650) 421-8100
ir@codexis.com
FAQ
When will Codexis (CDXS) report Q4 and fiscal 2025 results?
How can investors access the Codexis (CDXS) earnings webcast on March 11, 2026?
What are the dial-in details for the Codexis (CDXS) March 11, 2026 conference call?
Will Codexis (CDXS) provide a replay of the March 11, 2026 earnings call?
What time is the Codexis (CDXS) management business update on March 11, 2026?
